ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Aquatic-derived Streptomyces cavourensis BA1 as a promising source of antibacterial metabolites against multidrug-resistant gram-negative pathogens.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant Gram-negative bacteria remain a major therapeutic challenge, highlighting the need for new antibacterial metabolites from underexplored microbial sources. This study investigated Streptomyces cavourensis strain BA1, isolated from the Zubaida fish farm southwest of Lake Burullus, Egypt, as a potential producer of antibacterial agents against multidrug-resistant Escherichia coli and Klebsiella pneumoniae. The isolate was characterized morphologically, microscopically, and molecularly, and its antibacterial activity was evaluated using culture filtrate and solvent fractions. Bioactive metabolites in the most active extract were analyzed by GC-MS and HPLC, while cytotoxicity against VERO cells and ultrastructural effects on bacterial cells were also assessed. Morphological and SEM observations showed branched mycelia and flexuous spore chains, and molecular analysis confirmed 100% similarity to S. cavourensis strain PES4. The culture filtrate exhibited marked bactericidal activity, whereas the ethyl acetate organic phase showed the strongest activity among solvent extracts, with MIC values of 0.125-0.5 µg/mL, exceeding the activity of ampicillin under the tested conditions. The extract showed a favorable in vitro safety profile, with a CC50 of 296.1 µg/mL against VERO cells. GC-MS revealed fatty acid derivatives, including 9,12-octadecadienoic acid and palmitic acid derivatives, while HPLC identified trans-ferulic acid, salicylic acid, and caffeic acid as antibacterial-associated phenolic/flavonoid compounds. SEM of treated bacteria demonstrated wrinkling, surface collapse, membrane damage, and cellular debris, suggesting disruption of cell envelope integrity. Overall, S. cavourensis BA1 represents a promising source of antibacterial metabolites, although genome sequencing, bioassay-guided purification, and mechanistic studies are required to confirm the active principles and therapeutic safety in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.